ACOG | tickerfilter.com

Fundamental analysis

36%

Profitability 35%

Dept financing 23%

Liquidity 75%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-12.41%

1 Month

-12.41%

3 Months

-20.31%

6 Months

-23.26%

1 Year

-8.14%

2 Year

-16.72%

Key data

Stock price

$5.08

P/E Ratio

0.00

DAY RANGE

$4.87 - $5.36

EPS

-$0.21

52 WEEK RANGE

$3.75 - $11.54

52 WEEK CHANGE

$0.40

MARKET CAP

106.849 M

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-20-2025

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$43,123

AVERAGE 30 VOLUME

$46,094

Company detail

CEO: Michael McFadden
Region: US
Website: www.alphacognition.com
Employees: 0
IPO year: 2021

Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

The Company is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease, for which there are limited or no treatment options. Alpha Cognition Canada Inc. became the Company’s wholly-owned subsidiary. Our principal executive offices are located at 1200 – 750 West Pender Street, Vancouver, British Columbia. Our offices in the United States are located at 20073 Fiddler’s Green, Frisco, Texas.

ACOG - Alpha Cognition Inc.